There is a limited amount of data on the binding of paracetamol to plasma proteins. It has been suggested that binding might influence the ability of some analytical methods to quantify the total amount of drug present in the plasma fraction-the basis of clinical experience in risk assessment and antidote usage. We have investigated the binding of paracetamol to plasma proteins using an ultrafiltration technique. In overdose and spiked uraemic plasma samples the mean percentage of paracetamol bound was 24'1 (ISD = 7 '0) with no significant correlation with drug levels or degree of uraemia. There is a small but significant increase in binding with increasing serum albumin concentration both in plasma (r s = 0 ' 549, P=0·014) and in pure serum albumin solutions (r s = 0 ' 848, P<O·(XH).
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Paracetamol is a widely used antipyretic and analgesic agent which is considered safe in therapeutic doses, but carries a risk of hepatic necrosis with overdosage which can be exacerbated by chronic alcohol abuse. The hepatotoxic effect of paracetamol overdose is thought to result from the formation of a reactive metabolite, probably N-acetyl-pbenzoquinonimine generated via the cytochrome P450 system, which acts upon constituent macromolecules of hepatocytes, Overdose occurs when the rate of formation of the reactive intermediate outstrips the availability of glutathione to conjugate it at this site. However, effective treatment in the form of N-acetylcysteine or methionine can protect the liver if given within 10-12 h of ingestion. Treatment is indicated if the plasma level of the drug rises above a line joining a plot of 1· 32 mmol/L at 4 hand O' 2 mmol/L at 15 h, on a semi-logarithmic scale.'
The measurement of paracetamol in plasma has also been used as a means of determining the rate of gastric emptying after administration of a bolus of the drug, as the drug is not absorbed Correspondence: T P Milligan.
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in the stomach but rapidly absorbed in the upper small intestine.?
The degree of binding of a drug to protein in the blood can have a profound effect on the pharmacokinetics of a drug, and binding may be compromised by coexisting liver or renal disease. It has been shown that the free level of drug in the plasma correlates better with pharmcological activity and it is presumed that significant protein binding will reduce the rate of removal by the liver and the kidney.? It is for these reasons that it has been suggested that measurement of drug levels in saliva may provide a means of readily assessing the level of free drug in plasma. Several studies have demonstrated a correlation between plasma and saliva paracetamol although the ratio between saliva and plasma depends on sampling time." Whilst this is not significant for detecting a high level it invalidates the use of salivary measurement in the assessment of gastric emptying."
The methods for the measurement of paracetamol in cases of suspected overdose have always been assumed to measure the total amounts of parent drug in the plasma. However, this may have been fortuitous, due to the predilution or pretreatment steps in the enzymatic and chromatographic methods. In 1990
Bramwell et al." described a method for determining paracetamol in whole blood directly (i.e. without any sample predilution) using chronoamperometry following enzymatic hydrolysis, in which they found a ratio of 0'66 for results compared with the enzymatic assay employed with the paired plasma sample. The authors concluded that the electrochemical method was determining only the free drug level and that furthermore this was the relevant fraction available for metabolism and for causing liver damage.
We have investigated the potential binding of paracetamol to serum proteins and purified human serum albumin in order to determine whether the degree of protein binding is a relevant issue in the assessment of blood levels of the drug.
MATERIALS AND METHODS
Human serum albumin (HSA) fraction V (lot No. 67F-9313) and paracetamol were obtained from Sigma Chemical Co. (Poole, UK). Aryl acylamide aminohydrolase (BC 3.5.1.13) was obtained from the Division of Biotechnology, CAMR, (Porton Down, UK).
Ultrafiltration
Ultrafiltration was carried out using the Centrisart 1 system (SM 13249 E, mol wt cut off 20 000 Da) from Sartorius Ltd (Epsom, UK) with centrifugation in an Omnifuge 2.0RS (Heraeus, Brentwood, UK). An aliquot of 500 ILL was ultrafiltered at 1250 x g for 5 min at 20 DC to produce 200 ILL of ultrafiltrate. Recovery experiments indicated no detectable binding of paracetamol to the ultrafiltration membrane. Under these conditions a constant level of free ligand was achieved. It had previously been demonstrated that, provided the ultrafiltrate did not exceed 40% of the initial volume the free ligand concentration remained constant. 7
Drug quantitation
The amount of paracetamol in the original serum samples, the ultrafiltrates and dialysates was measured using the enzymatic method described by Hammond et al. 8 A 50 ILL aliquot of sample was incubated for 5 min with 500 ILL of buffered aryl acylamide aminohydrolase followed by the addition of 2 mL of o-cresol in ammoniacal Paracetamol binding to serum proteins 493 copper sulphate. The method was calibrated using an aqueous standard in which the accuracy of the drug level was confirmed by comparison with the stated extinction coefficient at 257 nm. All paracetamol measurements were carried out in triplicate (SD<0·016mmol/L).
Samples
Studies were undertaken with a total of 32 sera from patients who had taken an overdose of paracetamol (16 men and 16 women all between 18 and 41 years of age; data was not available on other drugs taken; N-acetyl cystene had not been given at the time of sampling) and 21 sera from patients with varying degrees of renal impairment (serum creatinines between 21 and 1323JLffiol/L).
In addition solutions of pure human serum albumin were prepared, in isotonic phosphate buffered saline pH 7· 4, over a range from 5 to 50 giL. The uraemic sera and the pure albumin solutions were spiked with a pure dry preparation of paracetamol by careful gravimetric addition followed by gently mixing to achieve drug levels between 0·2 and 4·0 mmol/L in the sample. The mixtures were incubated at 37 DC for 1 h prior to analysis.
RESULTS

Proportion of drug bound
The measurement of drug in the ultrafiltrate and original sample were used to assess the relation between free and bound drug in the patients samples (both overdose and spiked uraemic). Percentage binding of paracetamol was calculated as (total paracetamol-free paracetamol (ultrafiltratejj/total paracetamol. The data are plotted in Fig. I indicating that the mean proportion of drug bound is 24· 1% (1SD = 7 . 0); whilst a trend toward less binding at higher drug levels can be seen, this is not statistically significant (Spearman rank correlation coefficient (r s ) = -0,209 for overdose and -0'356 for spiked renal samples, P=0·278 and 0'121, respectively).
Influence of serum albumin level
The proportion of drug bound was compared with the level of the serum albumin (measured by a BCG dye binding method) for the samples from overdose patients. The data shown in Fig. 2 indicates that there is a small but significant increase in binding with increasing albumin (r s=0'549, P=0·014). and covering a range of drug concentrations. The data in Fig. 4 indicates that the proportion of drug binding increases with the amount of albumin present in the solution (r.=0·848, P<O·OOI).
DISCUSSION
The degree of binding of a drug to plasma proteins plays an important role in the metabolism of the drug as it is only the free fraction that diffuses into tissues producing the pharmacological effect. The extent of protein binding can also influence the elimination characteristics of the drug. In the case of a drug which demonstrates a significant degree of binding to protein, the nature of the binding forces, the presence of other molecules that compete for binding sites, and the level of binding protein may all influence the availability of the drug.? The nature of the binding of drug to protein, in particular, may also influence the quantitation of the drug; drugs that are tightly bound may require a releasing agent in order to determine the total amount of drug present.
The results presented in this paper indicate that a relatively small proportion of paracetamol is bound to serum proteins, between 20 and 25070 in most cases. These observations accord with those of Gazzard et 01. 10 who used heparinized and citrated plasma to study the paracetamol binding. These authors found no binding at therapeutic levels but at toxic levels (1. 7 mmollL) the binding was between 15 and 21%; in samples of plasma of patients who had taken an overdose of drug, the binding ranged between 8 and 43%. Influence of level of uraemia The proportion of drug bound was compared with the level of the serum creatinine (measured by a kinetic Jaffe method) for the samples from the uraemic patients to which paracetamol added to serum. The data shown in Fig. 3 indicate that there is no significant change in the drug binding characteristics as the degree of uraemia increases (r.=O·215, P=0·336). In this study there appeared to be no obvious correlation between the degree of protein binding and the amount of drug present; the higher level of binding found at low free drug levels may reflect imprecision of the methods at low drug levels. However, there appeared to be a weak positive correlation between the level of drug binding and the albumin concentration.
Lowenthal et a/. I I employed equilibrium dialysis to study protein binding of paracetamol in plasma from anephric patients (creatinine levels varied between 7· 3 and 24' 0 mg/l DO mL) and found less than 10% binding using a phosphate buffer system. The data presented in this paper whilst showing a higher overall level of binding, does not indicate any changes with increasing levels of uraemia; in the case of many drugs where there is appreciable protein binding then the proportion of free drug would be likely to vary with the level of uraemia as the drug is displaced by toxic compounds retained in the blood. In a study of the protein binding of several p-substituted acetanilides, Dearden and Tomlinson'? looked at the question from a different standpoint, using a dynamic dialysis method to study the binding of paracetamol to bovine serum albumin. These authors found that the binding enthalpies were sufficiently low to achieve ready dissociation of any drug protein complex at body temperature and concluded that the protein binding was minimal.
Finally, it has been shown that paracetamol readily passes across the placenta" and cases of neonatal poisoning have been reported. In an experimental study to predict the extent of diffusion of paracetamol into breast milk, Paracetamo/ binding to serum proteins 495 crossing another membrane barrier, McNamara et a/. 14 studied plasma and milk levels of paracetamol given to rabbits. These authors found only limited binding of the drug to proteins. Thus, the body of evidence available would suggest that there is little evidence of significant binding of paracetamol to serum proteins and that any binding that does exist does not play any important role in the disposition and fate of the drug. The data presented in this paper confirms the generally held view that only a small proportion of paracetamol is bound to serum proteins (10-20%) and that this degree of protein binding is unlikely to have a major influence on the measurement of the drug. This level of binding is less than would have been predicted by Bramwell et al. 6 if the difference in their results from the reference procedure had been due to protein binding; subsequently, a further evaluation of the enzyme mediated electrochemical technique was reported by Jones et a/. 15 which demonstrated better agreement with a highperformance liquid chromatography (HPLC) technique (slope of correlation = o·92) although there was no data to show that both methods were calibrated with the same material.
